Format

Send to

Choose Destination
Arch Otolaryngol Head Neck Surg. 1999 Dec;125(12):1305-10.

Beta-carotene produces sustained remissions in patients with oral leukoplakia: results of a multicenter prospective trial.

Author information

1
Arizona Cancer Center, University of Arizona, Southern Arizona Veterans' Affairs Healthcare System, Tucson 85723, USA. hgarewal@azcc.arizona.edu

Abstract

BACKGROUND:

Beta-Carotene has been reported to produce regressions in patients with oral leukoplakia, a premalignant lesion. However, previous studies have all been of short duration, with clinical response as the end point.

OBJECTIVE:

To evaluate the duration of response and the need for maintenance therapy in subjects who respond to beta-carotene.

METHODS:

In this multicenter, double-blind, placebo-controlled trial, subjects were given beta-carotene, 60 mg/d, for 6 months. At 6 months, responders were randomized to continue beta-carotene or placebo therapy for 12 additional months.

RESULTS:

Fifty-four subjects were enrolled in the trial, with 50 being evaluable. At 6 months, 26 subjects (52%) had a clinical response. Twenty-three of the 26 responders completed the second, randomized phase. Only 2 (18%) of 11 in the beta-carotene arm and 2 (17%) of 12 in the placebo arm relapsed. Baseline biopsies were performed in all patients, with dysplasia being present in 19 (38%) of the 50 evaluable patients. A second biopsy was obtained at 6 months in 23 subjects who consented to this procedure. There was improvement of at least 1 grade of dysplasia in 9 (39%), with no change in 14 (61%). Nutritional intake was assessed using food frequency questionnaires. There was no change in carotenoid intake during the trial. Responders had a lower intake of dietary fiber, fruits, folate, and vitamin E supplements than did nonresponders. Beta-carotene levels were measured in plasma and oral cavity cells. Marked increases occurred during the 6-month induction. However, baseline levels were not restored in subjects taking placebo for 6 to 9 months after discontinuation of beta-carotene therapy.

CONCLUSIONS:

The activity of beta-carotene in patients with oral leukoplakia was confirmed. The responses produced were durable for 1 year.

PMID:
10604407
DOI:
10.1001/archotol.125.12.1305
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center